Mer­ck seeks more ap­provals for in­fec­tious dis­ease drug

Phar­ma gi­ant Mer­ck is look­ing to bag more in­di­ca­tions for its cy­tomegalovirus (CMV) treat­ment Pre­vymis.

The phar­ma an­nounced on Fri­day that the FDA has ac­cept­ed two NDAs for the drug, al­so known as leter­movir. Mer­ck is hop­ing to grab an­oth­er in­di­ca­tion to be used in the pre­ven­tion of CMV dis­ease in adults who re­ceive kid­ney trans­plants. The FDA has set the PDU­FA date for June 5.

A sec­ond NDA has al­so been put for­ward to ex­tend the use of Pre­vymis from 100 to 200 days in adults who re­ceive a bone mar­row stem cell trans­plant and who are at risk for CMV in­fec­tion. The PDU­FA date is set for Sept. 7.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER